{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T10:59:05Z","timestamp":1792234745283,"version":"4.4.0"},"reference-count":24,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,1,9]],"date-time":"2021-01-09T00:00:00Z","timestamp":1610150400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2021,1,9]],"date-time":"2021-01-09T00:00:00Z","timestamp":1610150400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Neuroinflammation"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Genetic variants and mutations in triggering receptor expressed in myeloid cells (TREM2) are associated with premature and late onset Alzheimer\u2019s disease (AD).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We developed a panel of monoclonal antibodies, the selected lead of which was avidly shown to bind the extracellular domain of human and murine TREM2.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>By engaging membrane-bound TREM2, the selected antibody was shown to promote their cellular proliferation, uptake of oligomeric beta amyloid\/apoptotic neurons, and activation in a Syk and Akt dependent manner. The antibody was shown to avidly bind soluble TREM2 in the CSF from AD patients and blunted the proinflammatory program driven by its intracerebral injection. Upon in vivo treatment, the antibody was shown to improve cognitive function in experimental amyloidopathy models and to facilitate plaque-associated microglial coverage and activation.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Thus, we describe a novel monoclonal antibody targeting membrane bound and soluble TREM2, that improves cognitive function by inducing microglial activation and attenuating chronic neuroinflammation.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12974-020-01980-5","type":"journal-article","created":{"date-parts":[[2021,1,9]],"date-time":"2021-01-09T04:10:20Z","timestamp":1610165420000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":101,"title":["Engagement of TREM2 by a novel monoclonal antibody induces activation of microglia and improves cognitive function in Alzheimer\u2019s disease models"],"prefix":"10.1186","volume":"18","author":[{"given":"Michael","family":"Fassler","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maya Saban","family":"Rappaport","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clara Benaim","family":"Cu\u00f1o","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacob","family":"George","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,1,9]]},"reference":[{"key":"1980_CR1","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1038\/s41467-018-08279-3","volume":"10","author":"D Felsky","year":"2019","unstructured":"Felsky D, Roostaei T, Nho K, Risacher SL, Bradshaw EM, Petyuk V, et al. Neuropathological correlates and genetic architecture of microglial activation in elderly human brain. Nat Commun. 2019;10:409.","journal-title":"Nat Commun"},{"key":"1980_CR2","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1001\/jamaneurol.2013.579","volume":"70","author":"RJ Guerreiro","year":"2013","unstructured":"Guerreiro RJ, Lohmann E, Bras JM, Gibbs JR, Rohrer JD, Gurunlian N, et al. Using exome sequencing to reveal mutations in TREM2 presenting as a frontotemporal dementia-like syndrome without bone involvement. JAMA Neurol. 2013a;70:78\u201384.","journal-title":"JAMA Neurol"},{"key":"1980_CR3","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1056\/NEJMoa1211851","volume":"368","author":"R Guerreiro","year":"2013","unstructured":"Guerreiro R, Wojtas A, Bras J, Carrasquillo M, Rogaeva E, Majounie E, et al. TREM2 variants in Alzheimer's disease. N Engl J Med. 2013b;368:117\u201327.","journal-title":"N Engl J Med"},{"key":"1980_CR4","doi-asserted-by":"publisher","first-page":"2051","DOI":"10.4049\/jimmunol.177.4.2051","volume":"177","author":"JA Hamerman","year":"2006","unstructured":"Hamerman JA, Jarjoura JR, Humphrey MB, Nakamura MC, Seaman WE, Lanier LL. Cutting edge: inhibition of TLR and FcR responses in macrophages by triggering receptor expressed on myeloid cells (TREM)-2 and DAP12. J Immunol. 2006;177:2051\u20135.","journal-title":"J Immunol"},{"key":"1980_CR5","doi-asserted-by":"publisher","first-page":"1144","DOI":"10.1111\/j.1471-4159.2009.06042.x","volume":"109","author":"CL Hsieh","year":"2009","unstructured":"Hsieh CL, Koike M, Spusta SC, Niemi EC, Yenari M, Nakamura MC, et al. A role for TREM2 ligands in the phagocytosis of apoptotic neuronal cells by microglia. J Neurochem. 2009;109:1144\u201356.","journal-title":"J Neurochem"},{"key":"1980_CR6","doi-asserted-by":"publisher","first-page":"637","DOI":"10.1523\/JNEUROSCI.2110-16.2016","volume":"37","author":"TR Jay","year":"2017","unstructured":"Jay TR, Hirsch AM, Broihier ML, Miller CM, Neilson LE, Ransohoff RM, et al. Disease progression-dependent effects of TREM2 deficiency in a mouse model of Alzheimer's disease. J Neurosci. 2017;37:637\u201347.","journal-title":"J Neurosci"},{"key":"1980_CR7","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1084\/jem.20142322","volume":"212","author":"TR Jay","year":"2015","unstructured":"Jay TR, Miller CM, Cheng PJ, Graham LC, Bemiller S, Broihier ML, et al. TREM2 deficiency eliminates TREM2+ inflammatory macrophages and ameliorates pathology in Alzheimer's disease mouse models. J Exp Med. 2015;212:287\u201395.","journal-title":"J Exp Med"},{"key":"1980_CR8","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1056\/NEJMoa1211103","volume":"368","author":"T Jonsson","year":"2013","unstructured":"Jonsson T, Stefansson H, Steinberg S, Jonsdottir I, Jonsson PV, Snaedal J, et al. Variant of TREM2 associated with the risk of Alzheimer's disease. N Engl J Med. 2013;368:107\u201316.","journal-title":"N Engl J Med"},{"key":"1980_CR9","doi-asserted-by":"publisher","first-page":"3384","DOI":"10.1523\/JNEUROSCI.2620-14.2015","volume":"35","author":"M Kawabori","year":"2015","unstructured":"Kawabori M, Kacimi R, Kauppinen T, Calosing C, Kim JY, Hsieh CL, et al. Triggering receptor expressed on myeloid cells 2 (TREM2) deficiency attenuates phagocytic activities of microglia and exacerbates ischemic damage in experimental stroke. J Neurosci. 2015;35:3384\u201396.","journal-title":"J Neurosci"},{"key":"1980_CR10","doi-asserted-by":"publisher","first-page":"243ra86","DOI":"10.1126\/scitranslmed.3009093","volume":"6","author":"G Kleinberger","year":"2014","unstructured":"Kleinberger G, Yamanishi Y, Suarez-Calvet M, Czirr E, Lohmann E, Cuyvers E, et al. TREM2 mutations implicated in neurodegeneration impair cell surface transport and phagocytosis. Sci Transl Med. 2014;6:243ra86.","journal-title":"Sci Transl Med"},{"key":"1980_CR11","doi-asserted-by":"publisher","first-page":"633","DOI":"10.1016\/j.celrep.2014.12.041","volume":"10","author":"M Matarin","year":"2015","unstructured":"Matarin M, Salih DA, Yasvoina M, Cummings DM, Guelfi S, Liu W, et al. A genome-wide gene-expression analysis and database in transgenic mice during development of amyloid or tau pathology. Cell Rep. 2015;10:633\u201344.","journal-title":"Cell Rep"},{"key":"1980_CR12","doi-asserted-by":"publisher","first-page":"10129","DOI":"10.1523\/JNEUROSCI.1202-06.2006","volume":"26","author":"H Oakley","year":"2006","unstructured":"Oakley H, Cole SL, Logan S, Maus E, Shao P, Craft J, et al. Intraneuronal beta-amyloid aggregates, neurodegeneration, and neuron loss in transgenic mice with five familial Alzheimer's disease mutations: potential factors in amyloid plaque formation. J Neurosci. 2006;26:10129\u201340.","journal-title":"J Neurosci"},{"key":"1980_CR13","doi-asserted-by":"publisher","first-page":"656","DOI":"10.1086\/342259","volume":"71","author":"J Paloneva","year":"2002","unstructured":"Paloneva J, Manninen T, Christman G, Hovanes K, Mandelin J, Adolfsson R, et al. Mutations in two genes encoding different subunits of a receptor signaling complex result in an identical disease phenotype. Am J Hum Genet. 2002;71:656\u201362.","journal-title":"Am J Hum Genet"},{"key":"1980_CR14","doi-asserted-by":"publisher","first-page":"925","DOI":"10.1007\/s00401-016-1533-5","volume":"131","author":"L Piccio","year":"2016","unstructured":"Piccio L, Deming Y, Del-Aguila JL, Ghezzi L, Holtzman DM, Fagan AM, et al. Cerebrospinal fluid soluble TREM2 is higher in Alzheimer disease and associated with mutation status. Acta Neuropathol. 2016;131:925\u201333.","journal-title":"Acta Neuropathol"},{"key":"1980_CR15","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0052982","volume":"8","author":"MW Sieber","year":"2013","unstructured":"Sieber MW, Jaenisch N, Brehm M, Guenther M, Linnartz-Gerlach B, Neumann H, et al. Attenuated inflammatory response in triggering receptor expressed on myeloid cells 2 (TREM2) knock-out mice following stroke. PLoS One. 2013;8:e52982.","journal-title":"PLoS One"},{"key":"1980_CR16","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1016\/j.tins.2013.12.001","volume":"37","author":"AM Smith","year":"2014","unstructured":"Smith AM, Dragunow M. The human side of microglia. Trends Neurosci. 2014;37:125\u201335.","journal-title":"Trends Neurosci"},{"key":"1980_CR17","doi-asserted-by":"publisher","first-page":"647","DOI":"10.1084\/jem.20041611","volume":"201","author":"K Takahashi","year":"2005","unstructured":"Takahashi K, Rochford CD, Neumann H. Clearance of apoptotic neurons without inflammation by microglial triggering receptor expressed on myeloid cells-2. J Exp Med. 2005;201:647\u201357.","journal-title":"J Exp Med"},{"key":"1980_CR18","doi-asserted-by":"publisher","first-page":"3520","DOI":"10.4049\/jimmunol.177.6.3520","volume":"177","author":"IR Turnbull","year":"2006","unstructured":"Turnbull IR, Gilfillan S, Cella M, Aoshi T, Miller M, Piccio L, et al. Cutting edge: TREM-2 attenuates macrophage activation. J Immunol. 2006;177:3520\u20134.","journal-title":"J Immunol"},{"key":"1980_CR19","doi-asserted-by":"publisher","first-page":"667","DOI":"10.1038\/s41582-018-0072-1","volume":"14","author":"TK Ulland","year":"2018","unstructured":"Ulland TK, Colonna M. TREM2 - a key player in microglial biology and Alzheimer disease. Nat Rev Neurol. 2018;14:667\u201375.","journal-title":"Nat Rev Neurol"},{"issue":"649-63","key":"1980_CR20","volume":"170","author":"TK Ulland","year":"2017","unstructured":"Ulland TK, Song WM, Huang SC, Ulrich JD, Sergushichev A, Beatty WL, et al. TREM2 maintains microglial metabolic fitness in Alzheimer's disease. Cell. 2017;170(649-63):e13.","journal-title":"Cell"},{"key":"1980_CR21","doi-asserted-by":"publisher","first-page":"703","DOI":"10.1038\/nrneurol.2017.147","volume":"13","author":"J Wang","year":"2017","unstructured":"Wang J, Gu BJ, Masters CL, Wang YJ. A systemic view of Alzheimer disease\u2014insights from amyloid-beta metabolism beyond the brain. Nat Rev Neurol. 2017;13:703.","journal-title":"Nat Rev Neurol"},{"key":"1980_CR22","doi-asserted-by":"publisher","first-page":"1061","DOI":"10.1016\/j.cell.2015.01.049","volume":"160","author":"Y Wang","year":"2015","unstructured":"Wang Y, Cella M, Mallinson K, Ulrich JD, Young KL, Robinette ML, et al. TREM2 lipid sensing sustains the microglial response in an Alzheimer's disease model. Cell. 2015;160:1061\u201371.","journal-title":"Cell"},{"key":"1980_CR23","doi-asserted-by":"publisher","first-page":"992","DOI":"10.15252\/emmm.201606370","volume":"8","author":"X Xiang","year":"2016","unstructured":"Xiang X, Werner G, Bohrmann B, Liesz A, Mazaheri F, Capell A, et al. TREM2 deficiency reduces the efficacy of immunotherapeutic amyloid clearance. EMBO Mol Med. 2016;8:992\u20131004.","journal-title":"EMBO Mol Med"},{"key":"1980_CR24","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1084\/jem.20160844","volume":"214","author":"L Zhong","year":"2017","unstructured":"Zhong L, Chen XF, Wang T, Wang Z, Liao C, Wang Z, et al. Soluble TREM2 induces inflammatory responses and enhances microglial survival. J Exp Med. 2017;214:597\u2013607.","journal-title":"J Exp Med"}],"container-title":["Journal of Neuroinflammation"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12974-020-01980-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12974-020-01980-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12974-020-01980-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,1,9]],"date-time":"2021-01-09T04:18:00Z","timestamp":1610165880000},"score":1,"resource":{"primary":{"URL":"https:\/\/jneuroinflammation.biomedcentral.com\/articles\/10.1186\/s12974-020-01980-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,1,9]]},"references-count":24,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["1980"],"URL":"https:\/\/doi.org\/10.1186\/s12974-020-01980-5","relation":{},"ISSN":["1742-2094"],"issn-type":[{"value":"1742-2094","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,1,9]]},"assertion":[{"value":"10 March 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 October 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 January 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Provided.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"MF and JG have written the patent on the antibody.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"19"}}